Proteomic Biomarkers of Atherosclerosis

  1. Padial, L.R. 1
  2. Vivanco, F. 23
  3. De La Cuesta, F. 2
  4. Alvarez-Llamas, G. 2
  5. Barderas, M.G. 24
  6. Darde, V.M. 2
  7. Diaz-Prieto, Natacha 4
  1. 1 Department of Cardiology. Hospital Virgen de la Salud, SESCAM, Toledo, Spain.
  2. 2 Department of Immunology. Fundación Jiménez Díaz, Madrid, Spain.
  3. 3 Department of Biochemistry and Molecular Biology I, Universidad Complutense, Proteomic Unit, Madrid, Spain.
  4. 4 Department of Vascular Pathophysiology. Hospital Nacional de Paraplejicos, SESCAM, Toledo, Spain.
Mostra les afiliacions +
Revista:
Biomarker Insights

ISSN: 1177-2719,  1177-2719

Any de publicació: 2008

Volum: 3

Pàgines: BMI.S488

Tipus: Article

DOI: 10.4137/BMI.S488 GOOGLE SCHOLAR lock_openAccés obert editor

Altres publicacions en: Biomarker Insights

Resum

Biomarkers provide a powerful approach to understanding the spectrum of cardiovascular diseases.They have application in screening, diagnostic, prognostication, prediction of recurrences and monitoring of therapy. The “omics” tool are becoming very useful in the development of new biomarkers incardiovascular diseases. Among them, proteomics is especially fi tted to look for new proteins in healthand disease and is playing a signifi cant role in the development of new diagnostic tools in cardiovascular diagnosis and prognosis. This review provides an overview of progress in applying proteomicsto atherosclerosis. First, we describe novel proteins identifi ed analysing atherosclerotic plaques directly.Careful analysis of proteins within the atherosclerotic vascular tissue can provide a repertoire of proteinsinvolved in vascular remodelling and atherogenesis. Second, we discuss recent data concerning proteinssecreted by atherosclerotic plaques. The defi nition of the atheroma plaque secretome resides in thatproteins secreted by arteries can be very good candidates of novel biomarkers. Finally we describeproteins that have been differentially expressed (versus controls) by individual cells which constituteatheroma plaques (endothelial cells, vascular smooth muscle cells, macrophages and foam cells) as wellas by circulating cells (monocytes, platelets) or novel biomarkers present in plasma.